[{"id":"52bb5c5d-556a-45d3-8898-dea38d69712f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02363491","created_at":"2021-01-18T11:15:06.236Z","updated_at":"2024-07-02T16:37:03.441Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT02363491","lead_sponsor":"Opsona Therapeutics Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • IL18 • IL23A • IL1B","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL10 • IL18 • IL23A • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tomaralimab (NM-101)"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2019-01-28"}]